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Abstract
Background: The multi-stage hypothesis suggests that cancers develop through a single defined series of genetic
alterations. This hypothesis was first suggested over 50 years ago based upon age-specific incidence data. However, recent
molecular studies of tumors indicate that multiple routes exist to the formation of cancer, not a single route. This parallel
route hypothesis has not been tested with age-specific incidence data.
Methodology/Principal Findings: To test the parallel route hypothesis, I formulated it in terms of a mathematical equation
and then tested whether this equation was consistent with age-specific incidence data compiled by the Surveillance
Epidemiology and End Results (SEER) cancer registries since 1973. I used the chi-squared goodness of fit test to measure
consistency. The age-specific incidence data from most human carcinomas, including those of the colon, lung, prostate, and
breast were consistent with the parallel route hypothesis. However, this hypothesis is only consistent if an immune sub-
population exists, one that will never develop carcinoma. Furthermore, breast carcinoma has two distinct forms of the
disease, and one of these occurs at significantly different rates in different racial groups.
Conclusions/Significance: I conclude that the parallel route hypothesis is consistent with the age-specific incidence data
only if carcinoma occurs in a distinct sub population, while the multi-stage hypothesis is inconsistent with this data.
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Introduction
The multi-stage hypothesis [1,2] states that cancers develop
through a series of genetic alterations. This hypothesis is
schematically indicated by the following diagram,
Gene1?Gene2?...?Genen?Cancer: Scheme 1 ðÞ
Alterations occur successively in n genes (Gene1, Gene2, ...,
Genen) before a tissue specific cancer develops. The process is best
studied in human colorectal cancers, where the first four genes in
the sequence have been identified as APC, K-ras, DCC, and p53 [2].
The multi-stage hypothesis was first suggested over 50 years ago
based upon an analysis of the age-specific incidence data [3,4].
This data consists of a histogram of the age at which a population
develops cancer. It has long been interpreted to suggest that four
to six rate-limiting events are required for the formation of cancer.
Some problems exist with the multi-stage hypothesis. The
sequence APC, K-ras, DCC, and p53 is not the only route to
developing colon cancer. This particular route accounts for a
subset: only about half of colorectal cancer patients have
detectable mutations in the APC gene [5], and alternative routes
have been identified that do not involve APC [6].
Anomalies also exist with the age-specific incidence data that
cannot be explained by the multi-stage hypothesis. The incidence
for several carcinomas drops at advanced ages [7,8]. Breast
carcinoma incidence data is very different than the other
carcinomas [9], and it varies depending on the race and
nationality of the population studied [10]. Prostate carcinoma
incidence increases much more rapidly with age than other
carcinomas, implying that 20 to 30 mutations are required for its
development.
Based on several molecular studies [11,12], it is now generally
accepted that multiple parallel routes exist to the formation of
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?Cancer: Scheme 2 ðÞ
This parallel route hypothesis is a generalization of the
multi-stage hypothesis. The number of routes, m, and the number
of genes involved in each route, n1,n2,n3,...,nm are not known for
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the age-specific incidence data, so too can the parallel route
hypothesis.
Mathematical models of the age-specific incidence of cancer
have been an important tool to understand the tumorigenesis
process [13,14]. For instance, Knudson’s two-hit hypothesis of
retinoblastoma age-incidence data led to the identification of the
first tumor suppressor gene, Rb1 [15]. One of the few pieces of
evidence about the human carcinogenesis process is epidemiolog-
ical data on the incidence as a function of age [16].
I tested the parallel routes hypothesis by comparing a
mathematical representation of it to the age-specific incidence
data for different forms of cancer. Following this, I examined the
implications of the hypothesis and attempted to better understand
some of the anomalies of the age-specific incidence data.
Results and Discussion
I tested the validity of the parallel routes hypothesis with the
most powerful dataset available, the Surveillance Epidemiology
and End Results 17 registries (SEER-17) data collected in the year
2000 for the age-specific incidence of colon carcinoma. The year
2000 data monitored 73 million people in the United States and
recorded over 22,000 cases of colon carcinoma. The population
under surveillance, an important factor, was directly measured by
the 2000 US Census data. Thus, this is the best data to use to test
this hypothesis.
The parallel route hypothesis is consistent with the colon
carcinoma age-specific incidence data, while the multi-stage
hypothesis is not. To determine this, I compared the mathematical
representation of the parallel route hypothesis, Equation 3, with
the age-specific incidence data. In the same manner, I also
compared the mathematical representation of the multi-stage
hypothesis (the Armitage-Doll model Equation 2 [4]) with the age-
specific incidence data. See Figure 1. (Figure S1 demonstrates that
the computer simulations accurately represent the Armitage Doll
model.) The specific results are that the probability one should
accept the parallel route hypothesis is 10{3 (x2~88, with 52
degrees of freedom), while the probability that one should accept
the multi-stage hypothesis, Equation 2, is 10{48 (x2~316, with 53
degrees of freedom), see Figure 1.
The measured values characterizing the fit of Equation 3 to the
data, x2~88 and p~10{3, are somewhat high. This is partly
caused by a slight, but significant, excess of colon carcinoma cases
that occurred at ages 65 and 66. This excess is probably due to the
increased access to medical care when Medicare eligibility begins
at 65. If the excess cases at ages 65 and 66 are removed, the values
characterizing the fit drop to x2~65 and p~10{1. In the SEER-9
data, which is less powerful, this effect is not noticeable.
I also compared the colon carcinoma data to the exact
representation of the multi-stage hypothesis, Equation 1. This
formulation has three parameters just like the formulation of the
parallel route hypothesis. I found that one should not accept this
formulation either, (x2~172, with 52 degrees of freedom,
p~10{17).
The mathematical equation (Equation 3) of the parallel routes
hypothesis has three parameters, and each has a well defined
meaning. The first parameter, a, describes the fraction of the total
Figure 1. This graph compares two different hypotheses for the development of carcinoma with the age-specific incidence data.
The multi-stage hypothesis, as represented by the Armitage-Doll model, Equation 2 [51], and parallel route hypothesis, represented by Equation 3.
The Armitage-Doll model is an approximation of the differential form of the Poisson process, Equation 1. Using this equation gives p~10{17,a
substantially better, but still clearly unacceptable fit. Thus, the parallel route hypothesis is clearly acceptable, while the multi-stage hypothesis is not.
The error bars represent 95% confidence intervals in the measured values.
doi:10.1371/journal.pone.0007053.g001
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greater than the actual fraction who develop the disease. The
parameter a can vary from 0 to 1. The second parameter, the
mean time, t, indicates the average time, measured from birth, for
the formation and detection of the cancer. This is a theoretical
average, the actual average will always be less, since many die
from other causes before getting cancer. One would expect that
environmental influences can affect this parameter, and that may
be one explanation for the variation of times observed in the
population. The third parameter, the standard deviation of the
time, s, quantifies this variation in the population. This variation
can be attributed to either intrinsically random processes, genetic
variation, or environmental differences within the population. It is
also a function of the number of parallel routes, m, as shown in
Scheme 2 and Figure S2.
Surprisingly, the age-specific incidence data implies that only
about one of every five could ever develop colon carcinomathrough
this process. This suggests the existence of two distinct sub-
populations that are determined either before birth or at a very
young age. One subpopulation is destined to develop colon
carcinoma, while the other will never develop it. Competing risk,
or death due to other diseases, does not confuse this interpretation,
since this age-specific data corrects for reductions in the population.
For the next test of the hypothesis, I used the SEER-9 data [17]
to perform 31 similar tests (one for each year from 1973 to 2003)
on the four most common types of carcinoma: lung, colon, breast,
and prostate carcinoma. The SEER-9 data monitors fewer people
than the SEER-17 data, but has been collected since 1973. Using
this data allows more independent tests of the hypothesis.
The parallel routes hypothesis was consistent with the age-
specific incidence date for lung and colon carcinomas for all 32
years. However, the results for prostate and breast carcinoma were
more complicated. See Figure 2. Detailed graphs of the data, along
with the parallel routes hypothesis, are shown for 2003 in Figure 3.
Figure 2. This graph quantitatively shows the agreement between the SEER-9 data and the hypotheses (Equations 3 and 4). The top
panel displays the agreement, as measured by a p-value, between lung and colon carcinoma and Equation 3, and between breast carcinoma and
Equation 4. In all cases the p-value, representing the probability that one should accept the hypothesis, is greater than 0.001, and in most cases it
exceeds 0.01. In contrast, the corresponding graph for prostate carcinoma and Equation 3 shows that the p-value always exceeded 0.01, until 1991
when it plunged below that level. Prostate carcinoma, post 1991, clearly cannot be explained by Equation 3, but it is in agreement with Equation 4.
The 1991 change corresponds to the widespread implementation of screening for prostate carcinoma using the PSA test.
doi:10.1371/journal.pone.0007053.g002
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to the disease is shown in Table 1.
Prostate carcinoma age-specific incidence data was consistent
with the parallel route hypothesis until 1991, see Figure 2. The
1991 time period corresponds to the widespread adoption of the
PSA serum test for prostate cancer screening. The PSA test was
first approved in 1986, but it was initially used only to monitor the
progress of prostate cancer patients. In 1991 a study [18] showed
that the best method of screening for prostate cancers is
measurement of serum PSA levels combined with digital rectal
exams. This radically changed the diagnosis procedure for prostate
carcinoma.
The age-specific incidence data measures the time from birth to
the diagnosis of carcinoma. This time includes two distinct
components. The first is the time from birth to the development of
the carcinoma. The second is the time from development of the
carcinoma to its diagnosis. For prostate carcinoma, the second
component is long; many prostate cancers grow slowly. The
introduction of widespread screening has substantially shortened
the second component of the time and thus changed the age-
specific incidence data.
Breast carcinoma has never (1973–2003) been consistent with
Equation 3. Instead, breast carcinoma could only be consistent
with the parallel routes hypothesis, if one assumes that three
Figure 3. This is a comparison between the hypotheses and the observed age-specific incidence of colon, lung, prostate, and breast
carcinomas in 2003 as recorded by the SEER-9 registries. In each case, the measured incidence is represented by a point and the 95%
confidence intervals by error bars. A solid line represents the hypothesis, (Equation 3 for colon, lung, and prostate carcinomas and Equation 4 breast
carcinomas) and the parameters for the model are indicated on the graph.
doi:10.1371/journal.pone.0007053.g003
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these sub-populations is not susceptible to the disease, while the
other two sub-populations can develop breast carcinoma. These
distinct sub-populations probably develop distinct forms of the
disease.
Other studies also suggest that two distinct forms of breast
carcinomas exist. Early-onset breast carcinoma is already a
recognized subclass of the disease, typically being described as
occurring in women before the age of 35 [19–21]. My results
indicate significant overlap between the early and late onset forms,
and age itself is insufficient to determine whether a woman has one
form of the disease or another. (Hence, I refer to these as breast
carcinoma A and breast carcinoma B). However, most cases
(about 80%) diagnosed before the age of 35 will be breast
carcinoma A. Early-onset disease is biologically distinct [22,23]
from the late onset version and also a more potent form of the
disease [24,25]. Furthermore, recent work comparing the age
distribution patterns for different histopathologic types of breast
cancer using smoothed density plots [26,27] found results similar
to this [28], including a bimodal distribution of age at diagnosis,
with one mode centered about 50 years, and the second about 70
years. Hence, my conclusion is consistent with an emerging view of
breast cancer [21].
The origin of these two distinct sub-populations that develop
breast carcinoma is unclear. One possibility, these correspond to
inherited and sporadic cancers, seems unlikely. Three of 211 (95%
confidence intervals, 0%–7.2%) breast cancer patients in a
population based study were found to have inherited mutations
in BRCA1 [29]. These small numbers of BRCA1 mutation breast
cancers are unlikely to be apparent in this data.
Finally, I applied this hypothesis to better understand the racial
disparity in breast cancer. This striking disparity exists in the
prognosis for breast cancer patients in the United States. Although
African-Americans are less likely to contract the disease, a
significantly larger percentage of these patients die from it,
compared to white patients. Furthermore this gap has been
increasing over the past few decades [30]. While the obvious
cause, unequal treatment, may be responsible for some of this
disparity, it is not responsible for all. A detailed study of over
20,000 breast cancer patients treated in the equal access
Department of Defense Health care system between 1980 and
1999 also revealed a consistent and growing disparity [31].
I reasoned that since early-onset breast cancer is known to be
more deadly [24,25] and that 80% of early-onset cases are breast
carcinoma A then perhaps the racial disparity exists because
African-American women may be less likely to develop breast
carcinoma B. To test this, I extracted age-specific incidence data
for the year 2000 for both African-American and white women
from the SEER-17 dataset. I simultaneously fit the mathematical
equation of breast carcinoma age-specific incidence (Equation 4)
to each data set. I used the constraint that the breast carcinoma A
parameters were identical for both African American and white
women, while the breast carcinoma B parameters could vary.
I found that the age-specific incidence is consistent with the
hypothesis that breast carcinoma A has no racial disparity, while
breast carcinoma B incidence has substantial racial disparity. See
Figure 4. Breast carcinoma B accounts for three quarters of the
cases of breast cancer in the United States. A test that could
distinguish breast carcinoma B from breast carcinoma A might
give promising prognosis information to many patients.
The results presented here indicate that the age-specific
incidence data for most human carcinomas is consistent with the
parallel route hypothesis as expressed in Equations 3 and 4. The
parallel routes hypothesis, then, implies (through the age specific-
incidence data) that only a subset of the population is susceptible to
developing each carcinoma. Other hypotheses may be consistent
with this equation, but the implications are not dependent upon
the hypothesis.
These implications, or predictions, can be tested. First, the age-
specific incidence of breast and prostate carcinomas should
decrease for those over 85 years of age. Second, cancer incidence
in international populations should follow the same equation here.
Finally, unlike prostate and colon carcinomas, breast carcinomas
form in two fundamentally different ways.
This hypothesis may provide useful guidance for whole genome
analysis of carcinomas. The genetic basis for some diseases [32]
have been identified using whole genome analysis, but it has not
shown similar success when applied to carcinomas [33,34]. Whole
genome analysis compares genomes of those who have cancer with
those who do not. At least two complications arise in this analysis.
First is the proper identification of samples without cancer, since it
is not possible to identify people who will never be diagnosed with
cancer. Second is that samples are usually drawn from peripheral
blood; these would only be sensitive to germ-line mutations.
Two changes in the approach to whole genome analysis might
be needed. First, an independent measure of the population that
will not develop carcinomas is needed. This analysis can provide
such a measure. Second, DNA samples need to be drawn directly
from the relevant tissue. Only about 40% of children who develop
retinoblastoma have a germline mutation [35]. If these statistics
are true for carcinomas, the current approach to whole genome
analysis will not be successful.
Finally, similar conclusions have been drawn by others [36–39]
using different methods. Other work on age-specific incidence has
focused on the two stage with clonal expansion model [40–44] and
on developing novel techniques for the analysis of this data
[8,45,46]. Different mechanisms could explain the existence of a
sub-populations susceptible to carcinoma. For instance, members
of this sub-population may have inherited susceptibility conferred
through low-penetrance alleles [47] or may have acquired a
somatic mutation early in life [48].
In conclusion, the parallel routes hypothesis is consistent with
the age-specific incidence data for most common forms of human
carcinoma. Furthermore, the age-specific incidence data suggest
that only a measurable sub-population is likely to contract
carcinoma.
Table 1. This table shows an estimate of the fraction of the
population susceptible to each form of carcinoma, as






Colon 20:01 :3 ðÞ % 5%
Lung (female) 9:40 :4 ðÞ % 6%
Lung (male) 16:60 :6 ðÞ % 8%
Breast A 5:10 :7 ðÞ % –
Breast B 17:21 :4 ðÞ % 12%
Prostate 25 1 ðÞ 16%
The estimate is given as the mean value measured in five recent years, with the
standard deviation given in parenthesis. It also gives the lifetime probability of
developing carcinoma for all races in the 17 SEER areas over the period of 2004–
2006. (The total lifetime probability of developing breast carcinoma is 12%.)
doi:10.1371/journal.pone.0007053.t001
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Mathematical Models
The multi-stage hypothesis implies that the cancer age-specific
incidence should follow a Poisson process. The differential form of
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where l is the expected number of events that occur per unit time
and k is the number of rate limiting events required before cancer
occurs. However, the age-specific incidence is typically modeled by
the Armitage Doll equation [4],
It ðÞ &atk{1, ð2Þ
where a is an arbitrary constant and k is again the number of rate
limiting events required before cancer occurs. This is an
approximation, valid for t%1=l, of Equation 1. The condition
t%1=l is equivalent to saying that only a small percentage of the
population develops cancer.
The parallel route hypothesis is a combination of an unknown
number of Poisson processes. Thus, the Central Limit Theorem
suggests that the age-specific incidence, It ðÞ , of carcinoma for the












where a represents the fraction of people susceptible to the cancer.
This is the well-known normal distribution, also called the
Gaussian distribution, or bell-shaped curve. The Supplemental
Information S1 shows that the application of the Central Limit
Theorem is appropriate when the number of parallel routes is
about 10. (An exact solution requires that a be reduced by the
fraction of people who have already developed cancer, see [49].
Since carcinoma occurs in a small percentage of the population, as
opposed to cancers in atomic bomb survivors, treating a as a
constant is an approximation good to better than 1%.)
If two distinct sub-populations can develop carcinoma through
a different set of processes, the observed age-specific incidence will































To test the hypothesis that carcinoma age-specific incidence
data follow Equation 2, or Equation 3, or Equation 4, two steps
are required. First, the unknown parameters, (a,t, and s, in the
case of Equation 3) must be determined; I used maximum
likelihood estimation to do so. Second, the probability that the
observed data was generated by the postulated equation is
determined. I used the chi-squared test for goodness-of-fit to
determine this probability.
Figure 4. The breast carcinoma disparity between African-American and white women is not due to breast carcinoma A, which
occurs at exactly the same rate, but solely due to a difference in breast carcinoma B. The data are from the SEER-17 database during the
year 2000 [17]. In each case, the measured incidence is represented by a point and the 95% confidence intervals by error bars. The dark solid lines
represents predicted incidence levels based upon the hypothesis, Equation 4, which is the sum of breast carcinoma A and breast carcinoma
B indicated by the other curves.
doi:10.1371/journal.pone.0007053.g004
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where Ok is the observed number of carcinoma cases and Ek is the
expected number of carcinoma cases in each of the k~i to 84 age
ranges. The SEER dataset provides counts of cancer cases (and
population data) in one year intervals from 0 to 84 years. It also
includes data on all cases for those greater than 85 years old, this
was excluded. The minimum age used, i years, was chosen so that
at least 10 cases were present in that year. It was typically in the
20s or 30s, depending on the cancer. The expected number of
cases, Ek, was obtained by multiplying the age-corrected incidence
function It ðÞ , by the population under surveillance in that age
range.
Once the parameters were estimated, the chi-squared value was
determined, from Equation 5. A p-value, or probability that the fit
should be accepted, was calculated based as the one-tailed
probability of the chi-squared distribution.
I took several measures to ensure over fitting was not a problem.
Over fitting can be caused by fitting an arbitrary mathematical
function with multiple free parameters to a dataset. The defining
characteristic of over fitting is the inability of the model to fit
multiple independent datasets. The first step I took is to fit
independent data sets from successive years. This gives me
confidence that the model is representative of the underlying data.
SEER Data
I tested the models, Equation 3 and Equation 4, by fitting them
to age-specific incidence data from different carcinomas. The age-
specific incidence data were recorded by the SEER 9 registries
[17]. The SEER registries have compiled cancer incidence
information on a large representative sub-population of US
residents since 1973. From this database, I selected patients
diagnosed in a particular year with carcinoma in the indicated
tissue. This excludes the small number with other types of cancers,
sarcomas for instance, which probably arise through a different
process. The calculation of confidence intervals are based upon the
method of Fay and Feuer [50].
I chose to analyze data for patients who were diagnosed in the
same year (2000, for instance), rather than those born in the same
year (a birth-cohort). Different factors could distort either data set.
Birth-cohort analysis is significantly distorted by changes in
medical practice and diagnostic technology. On the other hand,
changes in environmental carcinogens may distort period analysis
[42–44], like the data presented here. Detection technology for the
carcinomas presented here have dramatically improved over the
past 50 years. Hence, I focus on patients diagnosed in a single
year, while recognizing that their environmental exposure may be
different.
Model Comparison
I used SEER-17 colon carcinoma data from 2000 for both men
and women. This gave cancer cases and population under
surveillance by individual years. I excluded those ages where
fewer than ten cases were observed, ages less than 30. The data
then included 22,344 cases in patients from 30 to 84 years of age,
55 independent data points. I tested the hypothesis that each was
consistent with the data by first determining the parameters using
the maximum likelihood method, then determining the goodness-
of-fit by minimizing the x2 value.
Supporting Information
Supplemental Information S1 A file containing the supple-
mental information. One page of results and methods describing
Figures S1 and S2.
Found at: doi:10.1371/journal.pone.0007053.s001 (0.04 MB
PDF)
Figure S1 This graph presents the results of computer
simulations based upon the assumption that carcinoma occurs
through a single route, as depicted in Scheme 1. The points
represent the simulation results, while the solid line represents
Equation 1. The inset shows the log-log graph in the boxed region
as the cancer age-incidence is usually shown.
Found at: doi:10.1371/journal.pone.0007053.s002 (0.45 MB TIF)
Figure S2 This presents the results of computer simulations
based upon the assumption that carcinoma may occur through
multiple parallel routes. The four situations represent different
assumptions in the computer simulation of 1, 5, 20, or 50 different
routes along which carcinoma may occur. The solid lines represent
the best fit to each, from Equation 3. The single route simulation,
similar to that shown in Figure S1, is clearly not fit by the
equation. The 5 parallel routes exhibit slight systematic deviations
from the equation, but the 20 and 50 route assumptions are well
described by the equation.
Found at: doi:10.1371/journal.pone.0007053.s003 (1.26 MB TIF)
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